These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. [Efficacy of native carvedilol in patients with essential hypertension]. Yang T; Zhang Z; Jia Z; Lin S; Peng Y Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):153-6. PubMed ID: 11938776 [TBL] [Abstract][Full Text] [Related]
27. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure. Lund-Johansen P; Omvik P; Nordrehaug JE; White W J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146 [TBL] [Abstract][Full Text] [Related]
28. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. Ruilope LM Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028 [TBL] [Abstract][Full Text] [Related]
29. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise. Lund-Johansen P; Omvik P Eur Heart J; 1992 Feb; 13(2):281-6. PubMed ID: 1555629 [TBL] [Abstract][Full Text] [Related]
30. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study. Fassbinder W; Quarder O; Waltz A Int J Clin Pract; 1999; 53(7):519-22. PubMed ID: 10692737 [TBL] [Abstract][Full Text] [Related]
31. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Fogari R; Zoppi A; Poletti L; Marasi G; Mugellini A; Corradi L Am J Hypertens; 2001 Jan; 14(1):27-31. PubMed ID: 11206674 [TBL] [Abstract][Full Text] [Related]
32. Dose-effect relationship of carvedilol in essential hypertension. An open study. Ogihara T; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T; Arakawa K Drugs; 1988; 36 Suppl 6():75-81. PubMed ID: 2908305 [TBL] [Abstract][Full Text] [Related]
33. Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing. Kett MM; Denton KM; Boesen EI; Anderson WP Am J Hypertens; 2004 Feb; 17(2):161-6. PubMed ID: 14751659 [TBL] [Abstract][Full Text] [Related]
34. Follow-up of a method of twenty-four-hour indirect blood pressure monitoring: evaluation of carvedilol, a new antihypertensive agent. Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R Nephron; 1987; 47 Suppl 1():42-6. PubMed ID: 3320788 [TBL] [Abstract][Full Text] [Related]
35. Heart failure in a district general hospital: are target doses of beta-blockers realistic? Mehta PA; McDonagh S; Poole-Wilson PA; Grocott-Mason R; Dubrey SW QJM; 2004 Mar; 97(3):133-9. PubMed ID: 14976270 [TBL] [Abstract][Full Text] [Related]
36. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis. Silkauskaitė V; Kupčinskas J; Pranculis A; Jonaitis L; Petrenkienė V; Kupčinskas L Medicina (Kaunas); 2013; 49(11):467-73. PubMed ID: 24823927 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension. Miki S; Masumura H; Kaifu Y; Yuasa S J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982 [TBL] [Abstract][Full Text] [Related]
39. Effect of carvedilol on left ventricular function and mass in hypertension. Why HJ; Richardson PJ J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S50-4. PubMed ID: 1378151 [TBL] [Abstract][Full Text] [Related]
40. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Giugliano D; Marfella R; Acampora R; Giunta R; Coppola L; D'Onofrio F Diabetes Care; 1998 Apr; 21(4):631-6. PubMed ID: 9571355 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]